Australian-based company Akesa has taken a significant step in its Asia Pacific expansion, establishing a presence in Japan and appointing an experienced pharmaceutical executive to lead its operations in one of the world’s most demanding clinical research environments.
The company has named Chisako Mizutani as Country Manager for Japan, bringing more than two decades of experience in clinical research and leadership in contract research organisations. Her appointment comes as the company prepares to support pharmaceutical and sponsors navigating Japan’s complex regulatory and operational landscape.
Japan’s importance in global clinical development continues to rise, underpinned by its advanced healthcare system and increasing participation in multi-regional trials. Yet the market is widely regarded as one of the most complex, requiring deep regulatory knowledge, cultural fluency and precise operational execution. For many international sponsors, these challenges can become barriers without strong local expertise.
Akesa’s leadership sees this expansion as a direct response to those demands. “Japan is a critical market within our JAPAC growth strategy,” said George Vlachos, Co-CEO of Akesa. “Chisako’s leadership will strengthen our ability to deliver compliant, customer-centric clinical trial supply services for global sponsors operating in one of the world’s most complex research environments.”
Mizutani arrives with a track record of managing large-scale clinical programs and advising on regulatory and operational risk across Japan, the United States and Europe. Her most recent role as Senior Director, Customer Alliance at IQVIA Japan saw her overseeing major trials while maintaining strategic client relationships across multiple regions. Earlier in her career, she held senior positions at CMIC Holdings and Quintiles Japan, where she led Phase 1 to 3 studies across a wide range of therapeutic areas, including oncology, cardiovascular and infectious diseases.
As a licensed pharmacist, she brings a blend of scientific training and practical operational insight that aligns with the company’s focus on end-to-end clinical trial supply management. She emphasised the growing need for reliability and coordination in the region, noting that “Japan continues to grow in importance within global clinical development programs, but sponsors require strong local coordination and supply chain reliability,” and added that, “Akesa’s focus on compliant sourcing, dispensing, and end-to-end supply management aligns closely with the needs of sponsors operating in Japan and across the wider JAPAC region. Our growing regional presence will support both domestic and international trials.”